King's College London

Research portal

Dr Suresh Victor

Education/Academic qualification

  • Doctor of Medicine, Cerebral haemodynamics, University of Liverpool


Professional Qualifications

  • Fellowship of Royal College of Paediatrics and Child Health, FRCPCH

    1 Feb 2014
  • Certificate of completion of training (Neonatal Medicine), CCT Paediatrics and Neonatal Medicine

    5 Aug 1997 - 5 Mar 2007
  • Membership of Royal College of Paediatrics and Child Health, MRCPCH

    7 Jun 1999
  • Diploma in Child Health, DCh

    1 Mar 1994 - 21 Mar 1997
  • Bachelor of Medicine and Bachelor of Surgery, MBBS

    7 Aug 1987 - 10 Jan 1994

Research interests

The goal of my research programme is to repurpose and test in the clinic a variety of neuroprotective treatments that have reached sufficient proof of efficacy in animal and experimental models of neonatal brain injury.

Prematurity accounts for 11% of all births, and is the leading global cause of death and disability under 5 years of age. All forms of cerebral palsy are seen in preterm children. Over 30% of survivors following preterm birth experience neurocognitive and socio-emotional problems from early life lasting into adulthood. Psychiatric disorders are present in around 25% of preterm adolescentsPrematurity leads to the loss of 75 million disability adjusted life years per annum worldwide.  

In the term infant, brain injury is most commonly due to hypoxia-ischaemia during labour. Hypoxic ischemic encephalopathy (HIE) occurs in 1.5 to 2.5 per 1000 live births in high income countries. However, 99% of the disease burden is in low and middle income countries. There is an urgent need to develop treatment strategies which supplement the protective effect of therapeutic hypothermia in high income countries and is independently safe, effective and acceptable in low and middle income countries.  

I am the Chief Investigator of a phase1, randomised placebo controlled, single ascending dose trial to evaluate the safety, tolerability, and pharmacokinetics of cannabidiol in conjunction with hypothermia in neonates with moderate or severe hypoxic ischemic encephalopathy with commercial sponsorship. 

I have developed a new liquid preparation of a licensed drug after extensive formulation studies in collaboration with industry and pharmaceutical manufacturing units. Pre-clinical studies of this neuro-protective strategy have already shown promising results. Early phase clinical trials are being planned following further confirmation of efficacy in animal models of preterm brain injury.

In a sustained translational research programme, other neuroprotective agents are being developed for hypoxic ischemic encephalopathy and neonatal ventricular dilatation with external collaborators in preclinical studies. 

The bulk of the world's neonatal mortality and morbidity exists in low and middle income countries with limited access to neonatal intensive care facilities. A key objective of my research programme, is to ensure that treatment strategies being developed can also be implemented world-wide. 

I have considerable experience in conducting randomised trials in newborn babies. I have been the Chief Investigator of a multi-centre randomised trial of non-invasive ventilation in prematurity. I have also been in the trial management group of clinical trials on thyroxine supplementation and skin-care in newborn babies. 

Biographical details

Dr. Suresh Victor joined King's College London in August 2016. Prior to this he was worked as Senior Lecturer and Honorary Consultant Neonatologist at University of Manchester. He completed his CCT in Neonatal Medicine in 2007. He was awarded a PhD for his thesis on 'Cerebral electrical activity and cerebral fractional oxygen extraction in human preterm newborn infants' by University of Liverpool in 2007. 

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454